Vis AN - Search Results

1

Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.

Meijer D, Luiting HB, van Leeuwen PJ, Remmers S, Jansen BHE, Bodar YJL, Witteveen T, Schaake EE, van der Poel HG, Wondergem M, Busstra MB, Nieuwenhuijzen JA, Meijnen P, Brabander T, van Moorselaar RJA, Hendrikse NH, Oprea-Lager DE, Roobol MJ, Vis AN. Meijer D, et al. Among authors: vis an. J Urol. 2021 Apr;205(4):1100-1109. doi: 10.1097/JU.0000000000001437. Epub 2020 Nov 18. J Urol. 2021. PMID: 33207138

2

Prostate cancer detection at low prostate specific antigen.

Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Schröder FH, et al. Among authors: vis an. J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.

3

Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy.

Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH. Vis AN, et al. Urology. 2000 Oct 1;56(4):617-21. doi: 10.1016/s0090-4295(00)00681-6. Urology. 2000. PMID: 11018617

4

Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.

Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, van der Kwast TH. Vis AN, et al. J Urol. 2000 Dec;164(6):2156-61. J Urol. 2000. PMID: 11061947

5

Staging prostate cancer.

Hoedemaeker RF, Vis AN, Van Der Kwast TH. Hoedemaeker RF, et al. Among authors: vis an. Microsc Res Tech. 2000 Dec 1;51(5):423-9. doi: 10.1002/1097-0029(20001201)51:5<423::AID-JEMT4>3.0.CO;2-4. Microsc Res Tech. 2000. PMID: 11074612 Review.

6

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Schröder FH, et al. Among authors: vis an. Urology. 2001 Jan;57(1):83-90. doi: 10.1016/s0090-4295(00)00863-3. Urology. 2001. PMID: 11164149 Clinical Trial.

7

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

8

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. Among authors: vis an. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

9

The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.

Vis AN, Hoedemaeker RF, Roobol M, Schröder FH, van der Kwast TH. Vis AN, et al. Cancer. 2001 Aug 1;92(3):524-34. doi: 10.1002/1097-0142(20010801)92:3<524::aid-cncr1351>3.0.co;2-a. Cancer. 2001. PMID: 11505396

10

Feasibility of assessment of promoter methylation of the CD44 gene in serum of prostate cancer patients.

Vis AN, Oomen M, Schröder FH, van der Kwast TH. Vis AN, et al. Mol Urol. 2001 Winter;5(4):199-203. doi: 10.1089/10915360152745894. Mol Urol. 2001. PMID: 11790283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page